CD38: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD38. The page also collects GeneMedi's different modalities and formats products for CD38 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD38 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

Pre-made CD38-specific INN-index biosimilar (antibody&conjugates)-Daratumumab, Isatuximab, Modakafusp, Felzartamab, Mezagitamab, modakafusp alfa

Anti-CD38 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-ab-133	Pre-Made Daratumumab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody	Daratumumab		CD38	Whole mAb
GMP-Bios-ab-279	Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody	Isatuximab		CD38	Whole mAb
GMP-Bios-ab-352	Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody	Modakafusp		ADPRC	Whole mAb Fusion
GMP-Bios-ab-208	Pre-Made Felzartamab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody	Felzartamab		CD38	Whole mAb
GMP-Bios-ab-342	Pre-Made Mezagitamab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody	Mezagitamab		CD38	Whole mAb
GMP-Bios-INN-917	Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1	modakafusp alfa		CD38	Fusion Protein

Pre-made anti-CD38 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD38 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD38 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T10877-Ab	Anti-CD38 monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody